Convalescent plasma clinical trial ramps up

September 7, 2020

On the heels of FDA authorization of convalescent plasma as a treatment for COVID-19, UNC researchers are conducting a clinical trial to determine the safety and efficacy of plasma that includes a higher amount of neutralizing antibodies against SARS-CoV-2. The new Coronavirus-inactivating Plasma (CoVIP) research clinical trial is designed to determine the safety and efficacy … Continued

Wohl launches clinical trial, one of 25 sites nationally testing COVID-19 treatments

September 1, 2020

  UNC Institute for Global Health and Infectious Diseases researchers have begun phase 2 and phase 3 evaluations of promising treatments for COVID-19. The UNC School of Medicine joins more than 25 initial sites participating in the clinical trials through ACTIV-2, a public-private partnership sponsored by the NIH’s National Institute of Allergy and Infectious Diseases … Continued

ID faculty organize, conduct COVID-19 testing in hard-hit Lee County, NC

July 29, 2020

  It’s hot (especially wearing full PPE), it’s tedious, and it’s critical. A volunteer team of UNC infectious diseases faculty members along with UNC hospitalists has been conducting drive-up testing for COVID-19 in Sanford, NC, about 35 miles south of Chapel Hill, twice a month since June, seeing roughly 1,000 local residents so far this … Continued

Gay leading phase 3 trial of COVID-19 vaccine

July 28, 2020

In February 2020, as bits of data about the SARS-CoV-2 virus started to emerge, Cindy Gay, MD, MPH, and UNC infectious diseases colleagues began meeting to formulate a local response to the virus. They’ve met weekly ever since, resorting to Zoom calls once the university sent employees home in March. They’ve shared data, compared notes … Continued

Parr, medical students conduct first study of tocilizumab in treating COVID-19

May 19, 2020

  In the first COVID-19 case series of tocilizumab in the United States, UNC-Chapel Hill researchers report sobering results. They say the drug should be used judiciously until randomized clinical trials determine tocilizumab’s true efficacy. Meanwhile, medical students sidelined from clinical rotations by the virus conducted the research with lightning speed, all virtually. In the … Continued

Study finds three strains of resistant bacteria, identifying greater diversity

May 14, 2020

    A new study by the Multi-Drug-Resistant Organism Network of the Antibacterial Resistance Leadership Group (ARLG) has found that strains of carbapenem-resistant enterobacterales (CRE), a major threat to vulnerable patient populations, are more diverse than previously thought. The MDRO Network is led by UNC Infectious Diseases investigator David van Duin, MD, PhD. Analyzing patient … Continued

Schranz receives NIH grant to study patient care for drug-use related heart infections

May 6, 2020

Asher Schranz, MD, MPH, assistant professor of medicine in the division of infectious diseases, has received a grant from the NIH National Institute on Drug Abuse for the project “Drug-use associated infective endocarditis: Post-hospitalization outcomes and patient treatment preferences.” Schranz’s research is broadly focused on the intersection of infectious diseases and substance use disorders. He … Continued

Report from China: Linghua Li, MD, PhD, shares COVID-19 observations

March 21, 2020

Linghua Li, MD, PhD, is an infectious disease specialist and AIDS clinic director at Eighth People’s Hospital in Guangzhou, China. She did two years of postdoctoral training in infectious diseases at Duke University and at UNC, working with the Institute’s David Wohl, MD. Here, she reports from the frontlines on dealing with COVID-19 in Guangzhou, which is about 600 miles from … Continued